Application of Xuebijing injection in severe craniocerebral injury patients with coagulation disturbance

Abstract

Objective To study the therapeutic effect of Xuebijing injection in severe craniocerebral injury patients with coagulation disturbance. Methods Sixty-five patients were randomly divided into Xuebijing treatment group (n=35) and control group (n=30). They all received regular treatment, while Xuebijing treatment group received Xuebijing injection additionally (0.9% sodium chloride injection 100 mL adding 30 mL Xuebijing twice daily for a consecutive 10 d). Prothrombin time (PT), active partial thromboplastin time (APTT), levels of blood platelet (PLT), d-dimer (DD), tumor necrosis factor α (TNF-α), interleukin (IL)-6 and IL-8, and Glasgow coma scale (GCS) scores at different time points, progressive intracranial hemorrhage (PIH) rate within 72 h, survival rate of 28 d were compared between two groups. Results Coagulation in all patients after treatment was significantly improved as compared with that before treatment (P<0.05). At 72 h after treatment, the PT, APTT, and levels of DD and PLT in Xuebijing treatment group were significantly improved as compared with those in the control group (P<0.05); levels of TNF-α, IL-6 and IL-8 at 72 h after treatment in the treatment group ([1.41±0.32] ng/L, [80.4±25.1] ng/L and [5.17±0.59] ng/L) were significantly lower than those in the control group ([1.74±0.30] ng/L, [96.6±23.4] ng/L and [8.32±0.72] ng/L], P<0.05). The PIH rate within 72 h in the treatment group (31.4%) was significantly lower than that in the control group (46.7%, P<0.05). Conclusion Xuebijing injection could improve the abnormal coagulation and lower the PIH rate in severe craniocerebral injury patients with coagulation disturbance, possibly because Xuebijing injection could ameliorate inflammation. Key words: Xuebijing injection; Craniocerebral injury; Coagulation disturbance; Inflammation